Document is current
Any future updates will be listed below
-
Authors
Compte, Emilio J.
Cattle, Chloe J.
Lavender, Jason M.
Brown, Tiffany A.
Murray, Stuart B.
Capriotti, Matthew R.
Flentje, Annesa
Lubensky, Micah E.
Obedin-Maliver, Juno
Lunn, Mitchell R.
Nagata, Jason M.
-
Funding
Funding for this research was provided by:
Office of Extramural Research, National Institutes of Health (K23 MH115184, K08HL159350)
National Institute on Drug Abuse (K23DA039800)
National Institute of Diabetes and Digestive and Kidney Diseases (K12DK111028)
Patient-Centered Outcomes Research Institute (PPRN‐1501‐26848)
American Heart Association (CDA34760281)
- License Information
-
More Information
Article History
Received: 26 April 2022
Accepted: 24 June 2022
First Online: 6 July 2022
Declarations
:
: The University of California, San Francisco and Stanford University Institutional Review Boards approved this study (#16-21213). Written informed consent was obtained from all participants.
: Not applicable.
: Dr. Obedin-Maliver has consulted for Sage Therapeutics (5/2017) in a one-day advisory board, Ibis Reproductive Health (a non-for-profit research group; 3/2017–5/2018, 2020-present), Folx, Inc. (2020—present), and Hims Inc. (2019—present). Dr. Lunn has consulted for Hims Inc. (2019—present) and Folx, Inc. (2020). Dr. Flentje has consulted for Hopelab (2020). None of these roles present a conflict of interest with this work as described here. The other authors have no conflicts of interest to report.
